Press Release: IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting
92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expected median PFS based on age and tumor status; one patient from Cohort 2 remains alive and progression free at almost three years
Press Release: IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting - Newscast
Mon, 21 Oct 2024 04:41:00 GMT REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 ...
Sat, 19 Oct 2024 17:00:00 GMT Does your organization or business have an announcement to promote? The Marietta Daily Journal's self-service Press Release Portal can get your organization's announcement the placement it needs.
Fri, 18 Oct 2024 01:15:00 GMT Soon after, guided by a sudden pillar of light, he has a shocking reunion with Ayase Miharu, the first love from his previous life as Haruto Amakawa―― G123 is a free gaming service that allows ...
Thu, 17 Oct 2024 17:00:00 GMT As a label-free method it is also more economic and can now be deployed ... Biognosys will launch its latest SpectroDive software for targeted proteomics. The new release offers streamlined ...
Thu, 17 Oct 2024 06:19:00 GMT This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma ... Statements in this press release that are not strictly historical in ...
